Applied Therapeutics Displays Govorestat CMT-SORD Trial Results

Summary

Applied Therapeutics presented the 12-month results of its Inspire II/III clinical trial for govorestat targeting CMT-SORD at the 2025 Peripheral Nerve Society Annual Meeting. The trial showed a slowdown in disease progression and a significant reduction in mannitol levels, although the primary endpoint did not achieve statistical significance. The company remains committed to submitting a potential New Drug Application for govorestat in 2025, emphasizing its safety and efficacy in improving patient-reported outcomes and functional metrics with a continued observation period of 24 months.StockTitan

Impact Analysis

The presentation of the clinical trial results is a critical product milestone for Applied Therapeutics. First-order effects include the potential advancement of govorestat towards a New Drug Application submission, which could enhance growth prospects by introducing a new treatment option for CMT-SORD patients. However, the failure to achieve statistical significance for the primary endpoint poses a risk of regulatory challenges and may impact investor confidence. Second-order effects could influence peer companies developing treatments for similar conditions, as they may reassess their competitive standing or research strategies. From an investment perspective, opportunities might include options strategies to hedge against potential volatility in the company’s stock price due to the mixed trial results.StockTitan